Clinical Trials
85 trialsEACH
University College, London
AVENANCE
Pfizer
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
St. Jude Children's Research Hospital
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
Massachusetts General Hospital
GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer
Genome & Company
A-Brave
Istituto Oncologico Veneto IRCCS
A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer
University of Iowa
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
Memorial Sloan Kettering Cancer Center
JAVELIN Renal 101
Pfizer
SAMCO
Federation Francophone de Cancerologie Digestive
LATENT
AHS Cancer Control Alberta
ALARICE
The University of Hong Kong
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Study of Avelumab-M3814 Combinations
EMD Serono
A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
J-DART2
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
AMPLIFY-NEOVAC
German Cancer Research Center
AURA
Jules Bordet Institute
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
AVETRIC
Gruppo Oncologico del Nord-Ovest
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
Pfizer
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NET-002
Sunnybrook Health Sciences Centre
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
AVAIL-T
University of Birmingham
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
MERKLIN2
4SC AG
Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Gilead Sciences
JAVELIN Bladder 100
Pfizer
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
SOGUG
Spanish Oncology Genito-Urinary Group
Phase I/Ib Multiple Ascending Dose Study in China
Merck KGaA, Darmstadt, Germany
OU-SCC-ABC
University of Oklahoma
ARIES
Consorzio Oncotech
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Syndax Pharmaceuticals
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
Pfizer
PAVE-1
Promontory Therapeutics Inc.
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
NKGen Biotech, Inc.
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
AVANA
Gruppo Oncologico del Nord-Ovest
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company